Integrating DNA Methylation Measures to Improve Clinical Risk Assessment: Are We There Yet? The Case of BRCA1 Methylation Marks to Improve Clinical Risk Assessment of Breast Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-019-0720-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Building Risk-On-A-Chip Models to Improve Breast Cancer Risk Assessment and Prevention

Integrative Biology (United Kingdom)
BiochemistryBiophysics
2013English

Clinical Proteomics: Are We There Yet?

Analytical Chemistry
Analytical Chemistry
2003English

Hormonal Risk Factors for Breast Cancer and DNA Methylation

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2013English

Polygenic Risk Scores and Their Potential Clinical Use in Psychiatry: Are We There Yet?

Revista Brasileira de Psiquiatria
PsychiatryMental Health
2020English

Colonoscopy After Acute Diverticulitis: From Clinical Epidemiology to Clinical Management. Are We There Yet?

Gastrointestinal Endoscopy
Nuclear MedicineRadiologyImagingGastroenterology
2020English

Using Tsunami Deposits to Improve Assessment of Tsunami Risk

2002English

Risk Assessment for Hereditary Breast Cancer: BRCA1 and BRCA2

Canadian Oncology Nursing Journal
2010English

Breast Cancer Epigenetics: From DNA Methylation to microRNAs

Journal of Mammary Gland Biology and Neoplasia
Cancer ResearchOncology
2010English

Cancer Immunotherapy: Are We There Yet?

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy